新型生物瓣膜MITRIS RESILIA二尖瓣置换早期血流动力学与临床结果
单中心回顾性研究纳入66例2021年5月至2024年5月接受MITRIS RESILIA二尖瓣置换的患者,评估出院时、术后1年和2年的瓣膜血流动力学。平均压差分别为3.9±1.4 mmHg、4.0±2.0 mmHg和3.9±1.3 mmHg,术后有效瓣口面积1.52±0.50 cm2,无结构性瓣膜衰败或显著瓣周漏,2年全因死亡率免除率93.3%。
要点
- MITRIS RESILIA二尖瓣置换后早期平均压差稳定在3.9-4.0 mmHg左右
- 术后有效瓣口面积达1.52±0.50 cm2,各瓣膜尺寸均表现稳定
- 2年随访无结构性瓣膜衰败和显著瓣周漏,全因死亡率免除率93.3%
核心结论
- MITRIS RESILIA二尖瓣生物瓣膜在包括23 mm在内的所有尺寸中均表现出稳定的早期血流动力学。
- 未观察到结构性瓣膜衰败或瓣周漏,支持其用于二尖瓣置换的可行性。
研究设计与样本
- 单中心回顾性研究,纳入2021年5月至2024年5月接受MITRIS RESILIA二尖瓣置换的66例患者。
- 经胸超声心动图评估出院时、术后1年和2年的瓣膜血流动力学。
- 主要终点为早期瓣膜血流动力学,次要终点为总生存率和结构性瓣膜衰败。
主要发现
- 队列平均年龄75.0±5.8岁,男性占48.5%。
- 平均压差出院时3.9±1.4 mmHg,1年4.0±2.0 mmHg,2年3.9±1.3 mmHg。
- 术后有效瓣口面积为1.52±0.50 cm2。
- 无患者发生结构性瓣膜衰败或显著瓣周漏。
- 2年全因死亡率免除率为93.3%。
临床怎么用
- 对于需行二尖瓣置换的患者,MITRIS RESILIA可作为备选生物瓣膜,早期血流动力学稳定。
- 术后应定期行超声心动图评估瓣膜功能,关注远期耐久性。
局限性
- 单中心回顾性设计,样本量66例,随访时间仅2年。
- 需更长期随访研究确认瓣膜的远期耐久性和临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The MITRIS RESILIA mitral bioprosthesis is a novel pericardial valve developed to improve durability and haemodynamic performance. However, clinical data on its use in mitral valve replacement are limited. This single-center retrospective study aimed to evaluate the early haemodynamic performance and clinical outcomes of the MITRIS RESILIA valve in patients requiring mitral valve replacement. METHODS: We retrospectively reviewed data from 66 patients who underwent mitral valve replacement using MITRIS RESILIA between May 2021 and May 2024. Transthoracic echocardiography was used to assess valve haemodynamic performance at discharge, 1 year, and 2 years postoperatively. The primary end-point was early valve haemodynamics, and the secondary end-points were overall survival and structural valve deterioration. RESULTS: The mean age of the cohort was 75.0 ± 5.8 years, and 48.5% of the patients were male. The mean pressure gradient was 3.9 ± 1.4 mmHg at discharge, 4.0 ± 2.0 mmHg at 1 year, and 3.9 ± 1.3 mmHg at 2 years. The effective orifice area was 1.52 ± 0.50 cm2 after surgery. None of the patients experienced structural valve deterioration or significant paravalvular leak. The rate of freedom from all-cause mortality at 2 years was 93.3%. CONCLUSIONS: MITRIS RESILIA demonstrated stable early haemodynamic performance across all valve sizes, including the 23 mm prosthesis. No cases of structural valve deterioration or paravalvular leak were observed, supporting its feasibility for mitral valve replacement. Further studies with extended follow-up are required to confirm the long-term durability and clinical benefits of the valve.
引用
- Wada Y, Marui A, Nagasawa A, et al. Early Haemodynamic Performance and Clinical Outcomes of a Novel Bioprosthetic Mitral Valve. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40795650. doi:10.1093/icvts/ivaf186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。